Am J Psychiatry 157:4-15, January 2000
© 2000 American Psychiatric Association
Cholinesterase Inhibitors: A New Class of Psychotropic Compounds
Jeffrey L. Cummings, M.D.
OBJECTIVE: This article reviews evidence indicating that acetylcholinesterase inhibitors have psychotropic properties. METHOD: The author reviewed the English-language literature pertinent to the response of neuropsychiatric symptoms in Alzheimer’s disease and related conditions to cholinergic agents. RESULTS: The cholinergic system originates in the basal forebrain and projects diffusely to the cerebral cortex; the limbic and paralimbic regions receive the most abundant cholinergic projections. The basal forebrain nuclei are positioned at the interface of the limbic system and cerebral cortex, where they play a role in mediating emotional responses. The basal forebrain nuclei are atrophic in Alzheimer’s disease, leading to a widespread cholinergic deficit. The cholinergic disturbance may contribute to neuropsychiatric manifestations of the disease. The treatment of patients with Alzheimer’s disease with acetylcholinesterase inhibitors reduces neuropsychiatric symptoms, particularly apathy and visual hallucinations. In some studies, a variety of other neuropsychiatric symptoms have been reported to respond to treatment with acetylcholinesterase inhibitors. Response profiles vary among acetylcholinesterase inhibitors. CONCLUSIONS: Acetylcholinesterase inhibitors have psychotropic effects and may play an important role in controlling neuropsychiatric and behavioral disturbances in patients with Alzheimer’s disease. These agents also may contribute to the management of other disorders with cholinergic system abnormalities and neuropsychiatric symptoms. The beneficial response is most likely mediated through limbic cholinergic structures.
This article has been cited by other articles:
|
|
|
|
 
R. W. Buchanan, R. R. Conley, D. Dickinson, M. P. Ball, S. Feldman, J. M. Gold, and R. P. McMahon
Galantamine for the Treatment of Cognitive Impairments in People With Schizophrenia
Am J Psychiatry,
January 1, 2008;
165(1):
82 - 89.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Cummings, R. Doody, and C. Clark
Disease-modifying therapies for Alzheimer disease: Challenges to early intervention
Neurology,
October 16, 2007;
69(16):
1622 - 1634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Buchanan, R. Freedman, D. C. Javitt, A. Abi-Dargham, and J. A. Lieberman
Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia
Schizophr Bull,
September 1, 2007;
33(5):
1120 - 1130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Swanson and R. M. Carnahan
Dementia and Comorbidities: An Overview of Diagnosis and Management
Journal of Pharmacy Practice,
August 1, 2007;
20(4):
296 - 317.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. L. Cummings, E. Schneider, P. N. Tariot, S. M. Graham, and for the Memantine MEM-MD-02 Study Group
Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Neurology,
July 11, 2006;
67(1):
57 - 63.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. N. Tariot
Neuropsychiatric Features of Dementia: What is the Big Picture?
Am J Geriatr Psychiatry,
July 1, 2006;
14(7):
557 - 560.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Cummings, T. McRae, R. Zhang, and The Donepezil-Sertraline Study Group
Effects of Donepezil on Neuropsychiatric Symptoms in Patients With Dementia and Severe Behavioral Disorders
Am J Geriatr Psychiatry,
July 1, 2006;
14(7):
605 - 612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Jankowska, P. Ponikowski, M. F. Piepoli, W. Banasiak, S. D. Anker, and P. A. Poole-Wilson
Autonomic imbalance and immune activation in chronic heart failure - Pathophysiological links
Cardiovasc Res,
June 1, 2006;
70(3):
434 - 445.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Guerin, S. Andrieu, S. M Schneider, M. Milano, R. Boulahssass, P. Brocker, and B. Vellas
Different modes of weight loss in Alzheimer disease: a prospective study of 395 patients
Am. J. Clinical Nutrition,
August 1, 2005;
82(2):
435 - 441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Herrmann, K. Rabheru, J. Wang, and C. Binder
Galantamine Treatment of Problematic Behavior in Alzheimer Disease: Post-Hoc Analysis of Pooled Data From Three Large Trials
Am J Geriatr Psychiatry,
June 1, 2005;
13(6):
527 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N I Bohnen, D I Kaufer, R Hendrickson, L S Ivanco, B J Lopresti, R A Koeppe, C C Meltzer, G Constantine, J G Davis, C A Mathis, et al.
Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry,
March 1, 2005;
76(3):
315 - 319.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Tractenberg, M. F. Weiner, J. L. Cummings, M. B. Patterson, and L. J. Thal
Independence of Changes in Behavior From Cognition and Function in Community-Dwelling Persons With Alzheimer's Disease: A Factor Analytic Approach
J Neuropsychiatry Clin Neurosci,
February 1, 2005;
17(1):
51 - 60.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Olazaran, R. Muniz, B. Reisberg, J. Pena-Casanova, T. del Ser, A. J. Cruz-Jentoft, P. Serrano, E. Navarro, M. L. Garcia de la Rocha, A. Frank, et al.
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease
Neurology,
December 28, 2004;
63(12):
2348 - 2353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Grossberg, P. Irwin, A. Satlin, P. Mesenbrink, and R. Spiegel
Rivastigmine in Alzheimer Disease: Efficacy Over Two Years
Am J Geriatr Psychiatry,
August 1, 2004;
12(4):
420 - 431.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Herrmann and D. Knopman
Donepezil therapy for neuropsychiatric symptoms in AD: Methods make the message
Neurology,
July 27, 2004;
63(2):
200 - 201.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Holmes, D. Wilkinson, C. Dean, S. Vethanayagam, S. Olivieri, A. Langley, N. D. Pandita-Gunawardena, F. Hogg, C. Clare, and J. Damms
The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
Neurology,
July 27, 2004;
63(2):
214 - 219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Cummings
Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Focus,
April 1, 2004;
2(2):
239 - 252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Cummings, L. Schneider, P. N. Tariot, P. R. Kershaw, and W. Yuan
Reduction of Behavioral Disturbances and Caregiver Distress by Galantamine in Patients With Alzheimer's Disease
Am J Psychiatry,
March 1, 2004;
161(3):
532 - 538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Ismail and I. H. Richard
A Reality Test: How Well Do We Understand Psychosis in Parkinson's Disease?
J Neuropsychiatry Clin Neurosci,
February 1, 2004;
16(1):
8 - 18.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Bassiony and C. G. Lyketsos
Delusions and Hallucinations in Alzheimer's Disease: Review of the Brain Decade
Psychosomatics,
October 1, 2003;
44(5):
388 - 401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kurita, Y. Ochiai, Y. Kono, M. Suzuki, and K. Inoue
The Beneficial Effect of Donepezil on Visual Hallucinations in Three Patients with Parkinson's Disease
J Geriatr Psychiatry Neurol,
September 1, 2003;
16(3):
184 - 188.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. R. Porter, W. G. Buxton, L. A. Fairbanks, T. Strickland, S. M. O'Connor, S. Rosenberg-Thompson, and J. L. Cummings
Frequency and Characteristics of Anxiety Among Patients With Alzheimer's Disease and Related Dementias
J Neuropsychiatry Clin Neurosci,
May 1, 2003;
15(2):
180 - 186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Cummings
Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Am J Geriatr Psychiatry,
April 1, 2003;
11(2):
131 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. T. Grossberg and A. K. Desai
Management of Alzheimer's Disease
J. Gerontol. A Biol. Sci. Med. Sci.,
April 1, 2003;
58(4):
M331 - 353.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Clark and J. H.T. Karlawish
Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies
Ann Intern Med,
March 4, 2003;
138(5):
400 - 410.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Griffin, R. van Reekum, and C. Masanic
A Review of Cholinergic Agents in the Treatment of Neurobehavioral Deficits Following Traumatic Brain Injury
J Neuropsychiatry Clin Neurosci,
February 1, 2003;
15(1):
17 - 26.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N.-H. Trinh, J. Hoblyn, S. Mohanty, and K. Yaffe
Efficacy of Cholinesterase Inhibitors in the Treatment of Neuropsychiatric Symptoms and Functional Impairment in Alzheimer Disease: A Meta-analysis
JAMA,
January 8, 2003;
289(2):
210 - 216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Buttini, G.-Q. Yu, K. Shockley, Y. Huang, B. Jones, E. Masliah, M. Mallory, T. Yeo, F. M. Longo, and L. Mucke
Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform , Aging, and Overexpression of Amyloid beta Peptides But Not on Plaque Formation
J. Neurosci.,
December 15, 2002;
22(24):
10539 - 10548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G C Pluck and R G Brown
Apathy in Parkinson's disease
J. Neurol. Neurosurg. Psychiatry,
December 1, 2002;
73(6):
636 - 642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. LAWLOR
Managing behavioural and psychological symptoms in dementia
The British Journal of Psychiatry,
December 1, 2002;
181(6):
463 - 465.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Ikeda, J Brown, A J Holland, R Fukuhara, and J R Hodges
Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry,
October 1, 2002;
73(4):
371 - 376.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Cummings and G. Cole
Alzheimer Disease
JAMA,
May 8, 2002;
287(18):
2335 - 2338.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Alexopoulos, D. N. Kiosses, S. Klimstra, B. Kalayam, and M. L. Bruce
Clinical Presentation of the ""Depression-Executive Dysfunction Syndrome"" of Late Life
Am J Geriatr Psychiatry,
February 1, 2002;
10(1):
98 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. P. Lai, O. -F. Lai, J. Keene, M. M. Esiri, P. T. Francis, T. Hope, and C. P.L.-H. Chen
Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex
Neurology,
September 11, 2001;
57(5):
805 - 811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ikeda, K. Hokoishi, N. Maki, A. Nebu, N. Tachibana, K. Komori, K. Shigenobu, R. Fukuhara, and H. Tanabe
Increased prevalence of vascular dementia in Japan: A community-based epidemiological study
Neurology,
September 11, 2001;
57(5):
839 - 844.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Cummings, A. Nadel, D. Masterman, and P. A. Cyrus
Efficacy of Metrifonate in Improving the Psychiatric and Behavioral Disturbances of Patients with Alzheimer's Disease
J Geriatr Psychiatry Neurol,
June 1, 2001;
14(2):
101 - 108.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Lobotesis, J.D. Fenwick, A. Phipps, A. Ryman, A. Swann, C. Ballard, I.G. McKeith, and J.T. O'Brien
Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD
Neurology,
March 13, 2001;
56(5):
643 - 649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. S. Hu, N. Okamura, H. Arai, M. Higuchi, T. Matsui, M. Tashiro, M. Shinkawa, M. Itoh, T. Ido, and H. Sasaki
18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies
Neurology,
November 28, 2000;
55(10):
1575 - 1577.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2000
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
